Ipca Laboratories announced unaudited financial results for Q2 and H1 FY26. Standalone net total income increased by 7% to ₹1952.24 crores, while consolidated net total income rose by 9% to ₹2584.36 crores. Domestic formulations grew by 8%, and export income increased by 7%. The company reported improved EBITDA margins and a 25% increase in standalone net profit.
Financial Performance Highlights
Ipca Laboratories reported a strong financial performance for the second quarter and first half of fiscal year 2026. Here’s a summary of the key results:
- Standalone Net Total Income: ₹1952.24 crores, up 7%
- Consolidated Net Total Income: ₹2584.36 crores, up 9%
- Indian Formulations Income: ₹1018.90 crores, up 8%
- Exports Income: ₹813.65 crores, up 7%
Profitability and Margins
The company demonstrated improved profitability with enhanced EBITDA margins:
- Standalone EBITDA Margin: 25.46% in Q2 FY26 (vs. 22.89% in Q2 FY25)
- Consolidated EBITDA Margin: 21.68% in Q2 FY26 (vs. 19.10% in Q2 FY25)
Net Profit Growth
Ipca Laboratories also reported significant growth in net profit:
- Standalone Net Profit: ₹304.74 crores, up 25%
- Consolidated Net Profit: ₹282.57 crores, up 23%
H1 FY26 Performance Overview
The positive trend continued in the first half of FY26, with the following results:
- Standalone Net Total Income: ₹3724.16 crores, up 9%
- Consolidated Net Total Income: ₹4925.87 crores, up 10%
- Indian Formulations Income: ₹1979.91 crores, up 9%
- Exports Income: ₹1513.41 crores, up 12%
Earnings Per Share
The earnings per share also saw substantial increases:
- Standalone EPS: ₹12.01 in Q2 FY26, up 25%
- Consolidated EPS: ₹11.14 in Q2 FY26, up 23%
Source: BSE
